Taken together, our results provided evidence that Interleukin-7/Interleukin-7 receptor induced cyclin D1 up-regulation via c-Fos/c-Jun pathway to promote proliferation of cells in lung cancer.
Although random forest analysis showed IL7R and IL10 SNPs as being associated with risk for lung cancer among African-Americans, it also identified TNFRSF10A SNP as an important predictor.
IL7R mutations are also frequently found in patients with lung cancer, but whereas in pediatric T-ALL IL7R mutations are "drivers" (consisting of gain-of-function mutations within a narrow 50-base pair interval at exon 6 that confer cytokine-independent cell growth and promote tumor transformation), in lung cancer, mutations are substitution mutations randomly distributed across the gene and are probably only "passenger" events.
Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.